HB Wealth Management LLC Takes Position in Astrazeneca Plc $AZN

HB Wealth Management LLC bought a new position in shares of Astrazeneca Plc (NYSE:AZN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 25,953 shares of the company’s stock, valued at approximately $4,902,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Mascoma Wealth Management LLC bought a new position in Astrazeneca in the 1st quarter valued at about $26,000. MV Capital Management Inc. bought a new stake in shares of Astrazeneca during the fourth quarter worth approximately $26,000. Roxbury Financial LLC acquired a new position in shares of Astrazeneca in the second quarter valued at approximately $29,000. Reflection Asset Management acquired a new position in shares of Astrazeneca in the fourth quarter valued at approximately $31,000. Finally, Resources Management Corp CT ADV bought a new position in shares of Astrazeneca during the first quarter worth approximately $35,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AZN. The Goldman Sachs Group reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Barclays reissued a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $206.67.

Astrazeneca Price Performance

AZN stock opened at $162.62 on Tuesday. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. Astrazeneca Plc has a 12 month low of $145.79 and a 12 month high of $212.71. The firm has a market cap of $252.21 billion, a P/E ratio of 24.31, a P/E/G ratio of 1.27 and a beta of 0.25. The company’s 50-day moving average price is $168.65 and its two-hundred day moving average price is $183.69.

Astrazeneca (NYSE:AZN) last issued its earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. The company had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.17 EPS. On average, analysts anticipate that Astrazeneca Plc will post 10.19 earnings per share for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.